ASCO GI 2021 | Zanidatamab: HER2-targeting bispecific antibody in HER2-expressing GEA

Anthony B. El-Khoueiry, MD, Keck School of Medicine of USC, Los Angeles, CA, presents the results of a Phase I study evaluating zanidatamab, a HER2-targeting bispecific antibody in HER2-expressing gastroesophageal adenocarcinoma (GEA). Zanidatamab, both as a single agent and in combination with chemotherapy, is well tolerated with promising and durable anti-tumor activity in heavily pretreated GEA patients (including prior HER2-targeted therapy) and further investigation in HER2-expressing GEA is ongoing. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).